Janus Henderson Group PLC Sells 321,789 Shares of Amgen Inc. $AMGN

Janus Henderson Group PLC decreased its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 12.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,322,793 shares of the medical research company’s stock after selling 321,789 shares during the period. Janus Henderson Group PLC owned about 0.43% of Amgen worth $760,300,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in AMGN. Anfield Capital Management LLC increased its holdings in shares of Amgen by 1,000.0% during the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after buying an additional 70 shares in the last quarter. Dogwood Wealth Management LLC increased its holdings in shares of Amgen by 275.0% during the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after buying an additional 55 shares in the last quarter. Board of the Pension Protection Fund acquired a new stake in shares of Amgen during the fourth quarter worth approximately $26,000. Manning & Napier Advisors LLC increased its holdings in shares of Amgen by 49.2% during the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after buying an additional 32 shares in the last quarter. Finally, Olistico Wealth LLC acquired a new stake in shares of Amgen during the fourth quarter worth approximately $33,000. Institutional investors own 76.50% of the company’s stock.

Amgen Price Performance

AMGN opened at $341.66 on Thursday. The company has a fifty day moving average price of $341.01 and a two-hundred day moving average price of $345.86. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. Amgen Inc. has a 52 week low of $267.83 and a 52 week high of $391.29. The firm has a market capitalization of $184.40 billion, a PE ratio of 23.78, a P/E/G ratio of 3.49 and a beta of 0.42.

Amgen (NASDAQ:AMGN) last released its earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. During the same quarter in the previous year, the business earned $4.90 EPS. The business’s quarterly revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, analysts anticipate that Amgen Inc. will post 22.38 earnings per share for the current year.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the sale, the senior vice president owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. The trade was a 15.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.85% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $350.00 price objective on shares of Amgen in a report on Wednesday, April 8th. Erste Group Bank reaffirmed a “hold” rating on shares of Amgen in a report on Tuesday, May 5th. Royal Bank Of Canada raised their price objective on shares of Amgen from $360.00 to $370.00 and gave the stock an “outperform” rating in a report on Tuesday, April 7th. Truist Financial raised their price objective on shares of Amgen from $325.00 to $327.00 and gave the stock a “hold” rating in a report on Friday, May 1st. Finally, Morgan Stanley raised their price objective on shares of Amgen from $332.00 to $340.00 and gave the stock an “equal weight” rating in a report on Tuesday, June 9th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, fifteen have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $354.42.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.